Drug-resistant Non-Small Cell Lung Cancer has few treatments that are effective. This study examined the effects of CBD on this cancer type, and was published in February 2022 in the journal Cancers.
"Our study demonstrated that small molecular weight non-psychotropic phytochemical, cannabidiol (CBD), inhibits growth and metastasis of drug-resistant non-small cell lung cancer cells (NSCLC) cells in-vitro and in-vivo."
The study showed that CBD initiated apoptosis (cell death) of CR NSCLC cells, and reduced tumor progression and metastasis in a mouse xenograft model. Additionally, CBD was shown to suppress cancer stem cell properties and demonstrated the ability to inhibit the growth of CR cell lines by reducing NRF-2 and enhancing the generation of reactive oxygen species (ROS).
"Moreover, we show that CBD acts through Transient Receptor Potential Vanilloid-2 (TRPV2) to induce apoptosis, where TRPV2 is expressed on human lung adenocarcinoma tumors."
The full-text paper is here at the National Library of Medicine (US).